The Accelerating Medicines Partnership- Alzheimer’s Disease Target Discovery and Preclinical Validation (AMP-AD) has supported the generation of whole genome data from three studies: the MAYO RNAseq Study, the Mount Sinai Brain Bank, and the ROSMAP study. The Genome Center for AD (GCAD) has partnered with the investigators of these studies to generate a joint genotype called dataset consisting of the AMP-AD genomes along with the ADSP and other Alzheimer’s Disease and Related Dementia projects. Data were obtained directly from each AMP-AD investigator and harmonized by the Genome Center for AD on the VCPA1.1 pipeline. Additional information about each of the three studies can be obtained from the AMP-AD Knowledge Portal.